Early sales impress as Onyx's Kyprolis gets off to strong US start
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals' sales of its recently approved multiple myeloma drug Kyprolis (carfilzomib) are off to an impressive start as the company reported $18.6 million in third quarter 2012 net sales on 2 November for the second-generation proteasome inhibitor, which was launched in the middle of the quarter.